NCT06845514 Impact of Resistance Training Intensity on Blood Pressure
| NCT ID | NCT06845514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université de Sherbrooke |
| Condition | Blood Pressure Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-07-08 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the clinical trial is to understand the effect of two resistance training protocols employing different loading intensities (% of 1 repetition maximum; 1-RM), but with standardized effort intensity (2 repetitions in reserve; RIR) on post-exercise and ambulatory blood pressure in aging females. The main questions it aims to answer are: * to examine the acute effects of low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise with a standardized high effort intensity on post-exercise hypotension and ambulatory blood pressure responses in aging females; * deepen the understanding of the mechanisms underlying acute reductions in blood pressure in response to resistance exercise performed at different load intensities. To this end, autonomic activity will be estimated alongside the measurement of central arterial compliance (i.e., carotid artery), and serum biomarkers of endothelial function; * document the affective valence and enjoyment associated with low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise when performed at a high perceived effort. Researchers will compare the effect of: 1) a low load (LL-RE) intensity protocol consisting of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 2) high load (HL-RE) intensity protocol consisting of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 3) and a control condition (CON) consisting of a standardized non-fatiguing cognitive task. Participants will participate in: * A preliminary assessment visit; * Two familiarization visits to validate the exercise prescriptions; * Three experimental visits (CON, LL-RE, HL-RE).
Eligibility Criteria
Inclusion Criteria: * aged 50 to 70 years; * absence of menstruation for 12 consecutive months; * normal-high resting blood pressure (120 ≤ Systolic ≤ 139 mmHg and 80 ≤ Diastolic ≤ 89 mmHg) or stage 1 hypertension (140 ≤ Systolic ≤ 159 mmHg or 90 \< Diastolic ≤ 99 mmHg); * physically inactive (\< 150 minutes of structured aerobic physical activity per week); * and not engaging in regular resistance exercise (≥ 2 sessions per week) for more than 3 months during the year. Exclusion Criteria: * orthopedic limitations or other contraindications to resistance exercise; * scheduled surgery during the study; * unstable hypertension (≥ 160/100 mmHg); * diagnosis of type 2 diabetes; * cardiovascular event in the past 6 months or sequelae preventing exercise; * and initiation of hormonal replacement therapy (\< 4 months) known to affect blood pressure.
Contact & Investigator
Eléonor Riesco, Ph.D.
PRINCIPAL INVESTIGATOR
Université de Sherbrooke
Frequently Asked Questions
Who can join the NCT06845514 clinical trial?
This trial is open to female participants only, aged 50 Years or older, up to 70 Years, studying Blood Pressure Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06845514 currently recruiting?
Yes, NCT06845514 is actively recruiting participants. Contact the research team at e.riesco@usherbrooke.ca for enrollment information.
Where is the NCT06845514 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT06845514 clinical trial?
NCT06845514 is sponsored by Université de Sherbrooke. The principal investigator is Eléonor Riesco, Ph.D. at Université de Sherbrooke. The trial plans to enroll 36 participants.